Certrolizumab pegol decreases uveitis in open label study of SpA with past uveitis and HLAB27 group enriched for recurrence. Pre and post Rx rates of uveitis were compared. 80% reduction of uveitis but uncontrolled and unblinded. #ACR #ACR19 @RheumNow